Back to Search
Start Over
ERG expression can predict the outcome of docetaxel combinedwith androgen deprivation therapy in metastatic hormone-sensitiveprostate cancer
- Source :
- Urologic oncology. 37(4)
- Publication Year :
- 2018
-
Abstract
- Our study aimed to analyze the potential association between clinical parameters and ERG expression and the outcome of docetaxel chemotherapy among patients with metastatic hormone-sensitive prostate cancer.Fifty-five patients with metastatic hormone-sensitive prostate cancer were treated with docetaxel in addition to androgen deprivation therapy. Patient characteristics, clinical factors, and tumor expression of ERG by immunohistochemistry were analyzed with respect to therapeutic response and survival data.Relapse free survival (RFS) and overal survival (OS) were 10.5 and 40.4 months, respectively, and both correlated with PSA response (RFS: 16.8 with a ≥50% decrease in PSA vs. 5.9 months in the case of50% decrease, P0.001; OS: 40.4 vs. 11.6 months, respectively, P0.001). There was an association between OS and early progression (OS: 40.4 months with progression after 12 months vs. 17.9 months with progression within 12 months, P = 0.009). ERG expression was detected in 21 (42%) samples. ERG positivity was associated with favorable RFS (ERG pos. vs. neg.: 26.0 vs. 11.4 months, P = 0.003).ERG expression may have a potential predictive value with respect to the effectiveness and outcome of docetaxel chemotherapy combined with androgen deprivation therapy.
- Subjects :
- Oncology
Adult
Male
medicine.medical_specialty
genetic structures
Urology
medicine.medical_treatment
030232 urology & nephrology
Docetaxel
urologic and male genital diseases
Androgen deprivation therapy
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Transcriptional Regulator ERG
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Prospective Studies
Aged
Retrospective Studies
Chemotherapy
business.industry
Cancer
Androgen Antagonists
Middle Aged
medicine.disease
Survival Rate
Prostatic Neoplasms, Castration-Resistant
Treatment Outcome
030220 oncology & carcinogenesis
Immunohistochemistry
business
Erg
Hormone
medicine.drug
Subjects
Details
- ISSN :
- 18732496
- Volume :
- 37
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Urologic oncology
- Accession number :
- edsair.doi.dedup.....4e1b70d33a9f04b0b926a106e5608154